Apolipoproteins B and A1 in Ischemic Stroke Subtypes.
Ischemic stroke
apolipoprotein
large artery atherosclerosis
stroke subtypes
Journal
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
ISSN: 1532-8511
Titre abrégé: J Stroke Cerebrovasc Dis
Pays: United States
ID NLM: 9111633
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
29
03
2019
revised:
05
01
2020
accepted:
12
01
2020
pubmed:
15
2
2020
medline:
21
7
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Elevated serum apolipoprotein B and the apolipoprotein B/A1 ratio have been associated with ischemic stroke and intracranial atherosclerotic disease. We sought to assess the relationship between serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio with ischemic stroke subtypes and large artery atherosclerosis location. We evaluated serum apolipoprotein B and apolipoprotein A1 levels in consecutive, statin-naïve, adult ischemic stroke patients admitted to an academic medical center in southern India. We evaluated for differences in the mean serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio between patients with ischemic stroke attributed to intracranial atherosclerotic disease, extracranial atherosclerotic disease, small vessel disease, and cardioembolism. In secondary analysis, we assessed for differences in these serum apolipoproteins between patients with moderate-severe intracranial atherosclerotic disease and extracranial atherosclerotic disease, irrespective of ischemic stroke subtype. Among the 156 ischemic stroke patients enrolled in this study, there were no significant differences in serum levels of apolipoprotein B, apolipoprotein A1, and the apolipoprotein B/A1 ratio between patients with distinct ischemic stroke subtypes. No significant differences were found in serum levels of apolipoprotein B, A1 and the apolipoprotein B/A1 ratio between patients with moderate-severe intracranial atherosclerotic disease and moderate-severe extracranial atherosclerotic disease. Serum levels of apolipoprotein B and A1 did not differ between ischemic stroke subtypes. Additional studies are needed to validate our findings and to better understand the relationship between serum apolipoproteins and stroke.
Identifiants
pubmed: 32057650
pii: S1052-3057(20)30036-7
doi: 10.1016/j.jstrokecerebrovasdis.2020.104670
pmc: PMC7085346
mid: NIHMS1569270
pii:
doi:
Substances chimiques
APOA1 protein, human
0
APOB protein, human
0
Apolipoprotein A-I
0
Apolipoprotein B-100
0
Biomarkers
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104670Subventions
Organisme : FIC NIH HHS
ID : R25 TW009337
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Cerebrovasc Dis. 2006;21(5-6):323-8
pubmed: 16490941
Neurology. 2007 Jun 12;68(24):2099-106
pubmed: 17409371
Lancet. 2006 May 6;367(9521):1503-12
pubmed: 16679163
Clin Lab. 2015;61(11):1727-35
pubmed: 26731999
Lancet. 2010 Jul 10;376(9735):112-23
pubmed: 20561675
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Stroke. 2011 Nov;42(11):3040-6
pubmed: 21868729
Metab Brain Dis. 2015 Dec;30(6):1319-30
pubmed: 26363640
Eur J Neurol. 2013 Apr;20(4):671-80
pubmed: 23121297
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
pubmed: 21487090
Interv Neurol. 2014 Aug;2(4):153-9
pubmed: 25337084
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
J Neurosci Rural Pract. 2012 Jan;3(1):21-7
pubmed: 22346186